

Indonesia Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Indonesia		
2. Grant number: 17-IDN-18a-Y / 17-IDN-08e-Y		
3. Date of Decision Letter: August 26, 2016		
4. Date of the Partnership Framework Agreement: December, 2014		
5. Programme title: NVS, Measles-Rubella Campaign		
6. Vaccine type: Measles-Rubella		
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED		
8. Programme duration¹: 2017		
9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)		
	2017	Total ²
Programme Budget (US\$)	US\$27,769,500	US\$27,769,500
10. Vaccine introduction grant (in US\$): 3,915,000. Payable up to six months before vaccine introduction.		
11. Indicative annual amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ³		
Type of supplies to be purchased with Gavi funds in each year	2017	
Number of Measles-Rubella vaccines doses	41,227,700	
Number of AD syringes	38,432,600	
Number of re-constitution syringes	4,535,100	
Number of safety boxes	472,650	
Annual Amounts (US\$)	US\$27,769,500	

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

12. Procurement agency: n/a	
13. Self-procurement: Country has elected to self-procure vaccines and injection safety devices in lieu of procuring through a Gavi agency. The applicable terms of the Partnership Framework Agreement and relevant Gavi guidelines and policies on self-procurement shall apply.	
14. Co-financing obligations: Not applicable	
15. Operational support for campaigns: Not applicable	
16. Additional reporting requirements: Not applicable	
Reports and other information	Due dates
Campaign Technical Report (including the total quantities of vaccine and injection safety devices, as applicable, procured, and final costs)	3 months after the end of campaign
Country shall submit the final report of post campaign coverage survey and financial report to Gavi	Once available
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Following self-procurement, Country must submit a full report outlining the total quantities of vaccine, supply chain equipment and injection safety devices, as applicable, procured, and final costs to be compared against the budget allocated in this Decision Letter. Country must submit satisfactory evidence that it purchased the vaccine doses and related supplies communicated by Gavi in this Decision Letter, by submitting purchase orders, invoices and receipts. Any balance of Gavi funds disbursed in support of Country self-procurement should be reported to Gavi together with satisfactory evidence that the leftover funds have been used within the immunisation programme.	
17. Financial clarifications: Not applicable	
<i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i>	
18. Other conditions:	
Transfer of funds: Funding will be channelled through the Directorate of Surveillance, Quarantine and Matra Health Immunization. Disbursements for vaccine and operational costs will be based on satisfactory progress, and once vaccine becomes licensed and quality is satisfactory.	

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
August 26th, 2016